HOXA9 regulates miR-155 in hematopoietic cells by Hu, Yu-Long et al.
HOXA9 regulates miR-155 in hematopoietic cells
Yu-Long Hu, Stephen Fong, Corey Largman
1,y and Wei-Fang Shen
1,*
Department of Medicine, Department of Veterans Affairs Medical Center and University of California,
San Francisco, CA 94143, USA
Received August 26, 2009; Revised April 15, 2010; Accepted April 19, 2010
ABSTRACT
HOXA9-mediated up-regulation of miR-155 was
noted during an array-based analysis of microRNA
expression in Hoxa9
 / bone marrow (BM) cells.
HOXA9 induction of miR-155 was confirmed in
these samples, as well as in wild-type versus
Hoxa9-deficient marrow, using northern analysis
and qRT–PCR. Infection of wild-type BM with
HOXA9 expressing or GFP
+ control virus further
confirmed HOXA9-mediated regulation of miR-155.
miR-155 expression paralleled Hoxa9 mRNA expres-
sion in fractionated BM progenitors, being highest in
the stem cell enriched pools. HOXA9 capacity to
induce myeloid colony formation was blunted in
miR-155-deficient BM cells, indicating that miR-155
is a downstream mediator of HOXA9 function in
blood cells. Pu.1, an important regulator of
myelopoiesis, was identified as a putative down
stream target for miR-155. Although miR-155 was
shown to down-regulate the Pu.1 protein, HOXA9
did not appear to modulate Pu.1 expression in
murine BM cells.
INTRODUCTION
Hoxa9 is expressed in numerous tissues during develop-
ment including rib (1), limb (2), motor neuron progenitors
(3), reproductive tract (4) and mammary gland (5). Hoxa9
is also expressed in normal adult bone marrow (BM) (6,7)
and loss of Hoxa9 leads to multiple relatively mild defects
in normal hematopoiesis (8–10). HOXA9 is often
up-regulated in acute myeloid leukemias (AMLs; 11,12),
and in an analysis of 6817 genes, HOXA9 was the most
highly correlated with treatment failure in AML patients
(13). Forced expression of HOXA9 in murine BM cells in
culture results in immortalization of a myeloid progenitor
cell (14,15), whereas transplantation of HOXA9-infected
BM cells results in the eventual induction of AML (16).
More recently, we have shown that HOXA9 regulates its
DNA binding partner Meis1, and that deletion of one
Meis1 allele in Hoxa9 deﬁcient mice results in profound
Pre/pro-B cell defects (17).
Despite the broad expression of Hoxa9 and other Hox
genes, relatively little is known about how the HOX
proteins function. An important advance was the discov-
ery that many HOX proteins gain DNA binding speciﬁcity
by forming complexes with the PBX (18,19), MEIS1 (20)
and PREP1 (21) proteins. Although HOXA9 is capable of
binding DNA alone (22), it forms cooperative DNA
binding complexes with MEIS1 alone (20), as well as in
a triple complex with PBX proteins (23,24). Despite these
apparent advances and the publication of the HOXA9
transcriptome (25), only a few direct downstream targets
for HOXA9 have been conﬁrmed (26–28).
Following the early report that microRNAs (miRs)
regulate aspects of hematopoietic lineage commitment
(29), several studies have enumerated miR expression in
normal BM fractions as well as in various leukemias
(30,31). These studies have revealed that miRs play
diverse roles in hematopoietic lineage decisions as well
as in several types of leukemias. However, the regulation
of miR expression in BM remains relatively poorly under-
stood. Since the HOX proteins are thought to function as
DNA binding transcription factors, as part of ongoing
studies on the mechanism of action of the HOXA9
protein, we used an array analysis to identify downstream
miR gene targets in murine BM cells. This analysis showed
that HOXA9 up-regulates miR-155. HOXA9-mediated in-
duction of myeloid colonies was impaired in miR-155-
deﬁcient mice, suggesting that miR-155 mediates some
HOXA9 function(s) in BM cells. Although miR-155 was
shown to down-regulate the hematopoietic modulator,
Pu.1, HOXA9 did not alter Pu.1 protein levels, indicating
that miR-155 functions in other pathways as a down-
stream mediator of HOXA9 action.
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Mice
Hoxa9-deﬁcient mice have been described previously (10).
miR-155-deﬁcient mice were provided by Jackson
Laboratories (Bar Harbor, MA, USA) and were
re-derived from animals developed by Thai et al. (32).
Retroviral constructs and virus production
MSCV-HOXA9-IRES-EGFP (MIG-HOXA9) and
MSCV-HOXA9NS-IRES-EGFP, encoding a DNA
binding mutant (MIG-HOXA9NS) retroviral constructs
were described previously (28). A hairpin expression con-
struct for miR-155 was constructed by PCR ampliﬁcation
of the murine miR-155 sequence and 150nt of 50 and 30
genomic sequence, followed by cloning into the MDH
retroviral vector (29). High-titer retrovirus was obtained
by transfecting Phoenix amphotropic packaging cells
using Metafectene transfection reagent (Biontex
Laboratories, Munich, Germany). Virus-containing
medium was harvested at 48 and 72h after transfection,
ﬁltered through a 0.45-mm ﬁlter, and used without storing
or freezing.
BM cell culture and retroviral transduction
BM cells from wild-type, Hoxa9-deﬁcient mice, or
miR-155-deﬁcient animals were harvested 4 days after
intraperitoneal injection with 150mg/kg 5-ﬂuorouracil
and cultured in prestimulatory media consisting of
Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 20% heat-inactivated FCS, 100ng/ml recom-
binant murine (rm) SCF, 50ng/ml rm IL-6 and 10ng/ml
rm IL-3 (StemCell Technologies, Vancouver, BC, Canada)
for 48h. Mouse BM cells were infected with retrovirus on
two consecutive days by spinoculation in the presence of
4mg/ml polybrene (Sigma, St Louis, MO, USA).
Analysis of miRs regulated by HOXA9 in murine
BM cells
Total RNA from GFP
+Hoxa9
 / BM cells, infected with
retrovirus expressing HOXA9-IRES-GFP, HOXA9NS-
IRES-GFP or MIG vector alone, was harvested in lysis
buﬀer (Ambion, #1931). Control and test miRs were
labeled with Cy5 (Alexa Fluor 647, Invitrogen #A32757;
Ambion labeling kit #1562) and hybridized to an Ambion
miR array containing 397 unique miRs (Ambion
#1566V1), according to the manufacturer’s instructions.
Microarrays were analyzed using GenePix software. miR
analysis was performed in triplicate on two separate sets
of infected BM samples. All values are means ± SD. A
P<0.05 denoted the presence of a statistically signiﬁcant
diﬀerence. Statistical analyses were performed using a
two-tailed Student t-test.
Quantitative real-time RT–PCR and northern
blotting analysis
GFP
+-sorted BM cells from the diﬀerent MIG-,
MIG-HOXA9- or MIG-HOXA9NS-infected cells were
resuspended in lysis buﬀer (#1931, Ambion). BM
progenitors were sorted into long-term hematopoietic
stem cells (HSCs), short-term HSCs and early progenitor
pools through multichannel sorting (33). Equal amounts
of total RNA were reverse transcribed to cDNA using
Superscript II polymerase (Invitrogen). All PCR reactions
were performed in an ABI Prism 7900HT sequence detec-
tion system (Applied Biosystems, Foster City, CA, USA)
using FAM (Applied Biosystems) as described (7). qRT–
PCR was used to measure murine miR-155 or U6 RNA
levels by using Applied Biosystems kits (Applied
Biosystems). Northern blotting was performed using anti-
sense miR-155 or U6 probes. Statistical analyses were per-
formed using Student’s t-test.
Fluorescence-activated cell sorting analysis
Fluorescence-activated cell sorting (FACS) sorting of
primitive hematopoietic pools was performed following
the methods developed in the Weissman laboratory (33).
For the immunophenotyping of primitive marrow popu-
lations, the femurs and tibia of 15-day old mice were
ﬂushed with Hanks Balanced Salt Solution (Life
Technologies, Bethesda, MD, USA) supplemented with
2% fetal calf serum (FCS) and 2mM ethylenediaminete-
traacetic acid. Then the BM cells were incubated with
labeled antibodies for 30min on ice, washed with
cold-PBS twice and analyzed by FACS on Becton
Dickinson FACScan using Cellquest software (Becton
Dickinson, San Jose, CA, USA). Antibodies used for
BM cell staining included phycoerythrin (PE)-conjugated
Mac-1 (#553311), PE-Cy7-conjugated-Gr-1 (#552985),
PE-conjugated B220 (#553089), ﬂuorescein isothiocyanate
(FITC)-conjugated IgM, PE-conjugated CD71 (#553267),
PE-Cy7-conjugated Ter119 (#557853), FITC-conjugated
CD41 (#553848), PE-conjugated CD61 (#553347),
PE-conjugated Sca1 (#553108) and PE-Cy7-conjugated
cKit (#558163), all of which were purchased from BD
Pharmingen (BD Biosciences, San Diego, CA, USA).
Myeloid colony assays
CFU-myeloid colony assays (CFU-GM) were performed
by culturing 2 10
3 BM cells in M3434 medium (StemCell
Technologies). Colonies were enumerated 7 days after
plating (28).
RESULTS
HOXA9 regulates multiple miRs in BM cells
We previously described the cDNA transcriptome of the
HOXA9 protein (25). The initial impetus for this project
was to build on these data by describing the possible
downstream miR targets regulated by HOXA9. A diﬀer-
ential microarray analysis was performed using an
Ambion chip containing 397 miR probes with small
RNA from Hoxa9-deﬁcient BM cells retrovirally
infected with an MSCV vector expressing HOXA9 plus
GFP or a GFP vector control. Figure 1A shows the
relative expression levels of the HOXA9 and
HOXA9-NS proteins expressed from the retroviral
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deﬁcient BM cells. HoxA9 signiﬁcantly up-regulated 30
miRs but only down-regulated ﬁve miRs in murine BM
cells (Table 1). Interestingly, 22 of the most highly ex-
pressed miRs in murine BM were not altered by
HOXA9 expression. Among the putative miR targets
regulated by HOXA9 identiﬁed in this analysis, we
chose to focus on miR-155, which was up-regulated
1.56-fold (P=0.001) in the array analysis, because of
the published importance of this microRNA in hemato-
poiesis (34,35).
miR-155 is up-regulated by HOXA9
Northern blotting was initially used to conﬁrm the array
data for miR-155. Consistent with the array data,
miR-155 was 2.7-fold higher in wild-type marrow than
in Hoxa9-deﬁcient BM cells (Figure 1B). Retroviral-
mediated expression of HOXA9 in wild-type BM cells
caused a 2.3-fold increase in miR-155, while a HOXA9-
NS DNA binding mutant did not increase miR-155 sig-
niﬁcantly (Figure 1C). miR-155 is generated from the BIC
non-coding transcript (34). In order to gain insight as to
whether HOXA9 regulates miR-155 at the transcriptional
level, we analyzed the eﬀect of exogenous HOXA9 on BIC
expression in BM cells. HOXA9 produced an  10-fold
increase in BIC mRNA, whereas the HOXA9-NS
mutant was only able to minimally increase BIC expres-
sion (Figure 1D).
miR-155 expression parallels Hoxa9 mRNA expression
in BM progenitors and is highest in the stem cell pools
Because miR-155 has been reported to play a regulatory
role in hematopoiesis, we analyzed miR-155 expression in
fractionated HSC and progenitor pools. Consistent with
both a regulatory role for HOXA9 and a function for
miR-155 in hematopoiesis, miR155 expression was much
higher in the long- and short-term HSC pools than in the
other progenitor pools (Figure 2A). We have recently
reported that HOXA9 expression is also highest in the
long-term and short term HSC pools (17). Thus,
miR-155 expression closely parallels Hoxa9 mRNA ex-
pression during early hematopoiesis. It should be noted
that the levels of HOXA9 protein are too low to be
detected in the small numbers of BM stem cells that can
be obtained from FACS sorting.
miR-155 is downstream of Hoxa9 in murine BM cells
To determine whether miR-155 mediates some of the bio-
logical properties of HOXA9, we used the fact that infec-
tion of murine BM cells with HOXA9 leads to a
substantial expansion of myeloid progenitors as
measured by colony formation (28). Retroviral-mediated
expression of HOXA9 versus MIG control vector in
wild-type murine BM compared to miR-155
 / BM was
used to explore whether miR-155 was a downstream
mediator of Hoxa9 (see Figure 1A for an example of
HOXA9 expression generated using this system).
HOXA9 induced a 2.6-fold increase in myeloid colony
formation in wild-type BM cells (Figure 2B). In
contrast, when HOXA9 was expressed in miR-
155-deﬁcient BM, there was a statistically signiﬁcant
decrease in induction of myeloid colonies (P<0.018).
These results demonstrate that the stimulatory eﬀect of
HOXA9 on colony growth was blunted in miR-155-
deﬁcient BM cells, strongly suggesting that at least some
of the biological activity of HOXA9 in BM myeloid pro-
genitor cells is mediated by miR-155.
Figure 1. HOXA9 up-regulates miR-155 and BIC mRNA. (A) Western blot showing HOXA9 or HOXA9-NS protein expressed from a
GFP-expressing retroviral vector after infection of Hoxa9
 / BM cells. (B) Northern gel analysis showing that miR-155 was  2.7-fold higher in
wild-type BM cells compared to Hoxa9-deﬁcient cells. (C) Retroviral-mediated expression of HOXA9 caused a 2.3-fold increase in miR-155, while a
DNA binding mutant (HOXA9NS) did not signiﬁcantly change miR-155 levels. The arrowhead indicates the miR-155 primary hairpin form. (D) The
primary hairpin miR-155 is generated from the BIC transcript (34). Forced expression of HOXA9 produced a 10-fold increase in BIC message, while
the HOXA9NS mutant did not signiﬁcantly increase BIC mRNA.
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After showing that HOXA9 up-regulated miR-155, and
that miR-155 mediates at least some HOXA9
functionality, we used the available prediction programs
to identify Pu.1 as a putative target for miR-155 (36). Pu.1
is an ETS family transcription factor that has been shown
to play important regulatory roles in both normal
myelopoiesis and leukemogenesis (37). To test the eﬀects
of miR-155 on Pu.1 expression, we generated a retroviral
vector that expressed a miR-155 hairpin precursor.
Although this vector produced an  600-fold increase in
miR-155 in 293T cells (data not shown), miR-155 expres-
sion increased only 8-fold following viral infection of
wild-type BM cells (Figure 2C). Infection of either
wild-type or Hoxa9-deﬁcient BM cells with this miR-155
expression vector resulted in an  50% decrease in Pu.1
protein (Figure 2D and E), a ﬁnding that has been
reported by others since the inception of this work (38).
These ﬁndings strongly suggested that HOXA9 might
regulate Pu.1 via miR-155, and that this might be a sig-
niﬁcant window into understanding how the HOXA9
protein inﬂuences hematopoiesis. However, despite exten-
sive analysis, we could not convincingly demonstrate a
reproducible change in BM Pu.1 protein levels when
HOXA9 was infected into either normal or Hoxa9-deﬁ-
cient cells (data not shown). We have concluded from
these studies that the modulation of miR-155 by
HOXA9 is not reﬂected by changes in Pu.1 expression.
DISCUSSION
Although the HOXA9 homeodomain protein appears to
play important roles in numerous other tissues (1–5), we
have focused in this study on its role(s) in normal hem-
atopoiesis (29,39–43) and leukemia (40,44–46). In both
blood and other tissues, despite the presence of a DNA
binding domain and a presumption of transcriptional
regulatory activity, the HOXA9 mechanism(s) of action
remain relatively obscure. Although we have previously
described the HOXA9 transcriptome (25), relatively few
downstream targets have been authenticated. In this
regard, we have previously reported that Pim1 is a direct
downstream target (28). We also recently reported that
HOXA9 can regulate its DNA binding partner Meis1,
and that this process may be mediated by CREB1,
which appears to be a direct HOXA9 target (17).
Because of the dearth of well-understood mechanism to
describe HOXA9 function, we undertook the current
microarray-based survey of possible miR targets in BM
cells. However, given our subsequent ﬁndings that the
microarray survey data could be only partially conﬁrmed
by other methods used to assess miR expression (data not
shown), we place only limited emphasis on the survey
data. Nevertheless, some general trends were apparent;
(i) there was a small class of miRs that were extremely
highly expressed in BM, and none of these appeared to
be modulated by HOXA9; (ii) the great majority of miRs
interrogated were not highly expressed in BM cells;
(iii) among the ﬁve miRs moderately down-regulated
and the 30 moderately up-regulated by HOXA9, most of
the changes detected by the relatively crude array strategy
were modest.
Table 1. miRs regulated by HOXA9 in BM cells
miRNA Expression levels Fold change P-value
miRs down-regulated by HoxA9
miR-15b High 0.77±0.12 0.02
miR-23a High 0.40±0.06 0.01
miR-25 High 0.55±0.14 0.01
miR-320 High 0.78±0.02 0.01
miR-342 High 0.48±0.07 0.01
miRs up-regulated by HoxA9
miR-19b High 1.53±0.10 0.001
miR-106b High 1.43±0.38 0.03
miR-147 High 2.46±0.93 0.03
miR-155 High 1.56±0.24 0.001
miR-191 High 1.27±0.18 0.014
miR-297 High 2.21±0.29 0.0002
miR-122a Medium–high 2.67±1.60 0.04
miR-142-5p Medium 3.94±2.30 0.05
miR-302c-AS Medium 1.67±0.34 0.003
miR-124a-mm Medium–low 3.45±2.60 0.05
miR-142-3p Medium–low 3.98±1.80 0.04
miR-190 Medium–low 3.42±0.11 0.01
miR-211 Medium–low 3.50±2.01 0.01
miR-326 Medium–low 3.64±2.10 0.03
miR-525 Medium–low 5.07±1.20 0.0002
miR-34c Low 3.68±1.51 0.01
miR-98 Low 3.31±1.21 0.02
miR-181c Low 2.78±1.23 0.03
miR-200c Low 2.21±0.62 0.02
miR-301 Low 3.25±1.88 0.04
miR-383 Low 3.85±1.63 0.04
miR-422b-mm Low 2.24±1.15 0.04
miR-518b Low 4.64±0.79 0.0002
miR-524 Low 3.58±1.14 0.0004
miR-527 Low 3.29±0.18 0.003
miR-30e-3p Very low 3.81±1.58 0.02
miR-143 Very low 3.56±2.04 0.01
miR-204 Very low 4.13±2.14 0.01
miR-485-5p Very low 2.96±1.25 0.05
miR-518f Very low 4.98±1.58 0.004
Highly expressed miRs in BM, not regulated by HoxA9
let-7a–7i Very high 0.99±0.25 0.79
miR-21 Very high 1.03±0.13 0.67
miR-93 Very high 0.97±0.08 0.81
miR-103 Very high 0.96±0.45 0.71
miR-106 Very high 0.96±0.21 0.71
miR-107 Very high 1.00±0.24 0.90
miR-210 Very high 1.04±0.24 0.88
miR-223 Very high 1.03±0.22 0.90
miR-494 Very high 1.00±0.05 0.96
miR-22 High 1.03±0.25 0.85
miR-23b High 0.97±0.20 0.77
miR-26a,b High 1.00±0.28 0.95
miR-29a High 1.01±0.30 0.79
miR-30a-5p High 1.04±0.18 0.91
miR-30c High 1.03±0.38 0.92
miR-31 High 1.01±0.35 0.87
miR-103b High 1.08±0.28 0.75
miR-181a High 1.06±0.26 0.68
miR-185 High 1.08±0.34 0.79
miR-198 High 0.96±0.48 0.94
miR-221 High 0.99±0.10 0.88
miR-513 High 1.00±0.45 0.84
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to focus on miR-155 based primarily on published
evidence of a reported role in hematopoiesis and/or leu-
kemogenesis (34–35,38,47–49). One study reported that
transgenic mice in which miR-155 is strongly expressed
within the B-cell lineage develop lymphomas (48).
Another reported that miR-155 was over-expressed in
some AMLs and that forced expression of miR-155 in
murine BM induced a myeloproliferative disease (35).
Since forced Nup98-HOXA9 expression in murine BM
also produces a myeloproliferative state (50), while
HOXA9 alone appears to immortalize a promyelocytic
progenitor (14), the observation that HOXA9 up-regulates
miR-155, and that HOXA9 and miR-155 expression was
correlated in hematopoietic stem cells, suggested that this
process might partially explain HOXA9 mechanism of
action. Our data, showing that a DNA binding mutant
form of HOXA9 is incapable of up-regulating miR-155,
further supports a working model for HOXA9 functioning
as a transcription factor to regulate miR155 and subse-
quent down stream targets. In support of this hypothesis,
we have now also shown that miR-155 appears to act as a
downstream mediator of HOXA9, since the proliferative
eﬀects of HOXA9 on BM progenitors is blunted in
miR-155-deﬁcient cells. In an attempt to discover a mech-
anism by which miR-155 might mediate the action of
HOXA9, we used the existing prediction programs to
identify Pu.1, an important regulatory protein for
myelopoiesis and leukemogenesis (51), as a putative down-
stream target of miR-155. Our data conﬁrmed this
Figure 2. miR-155 expression is highest in BM stem cell pools, miR-155 is downstream of Hoxa9, and miR-155 down-regulates Pu.1. (A) miR-155
was expressed predominantly within the stem cell-enriched pools in FACS-fractionated BM progenitors. LT, long-term HSC pool; ST, short-term
HSC pool; MPP, multipotential progenitor pool; CMP, common myeloid progenitor pool; MEP, myeloid–erythroid progenitor pool; and GMP,
granulocyte–monocyte progenitor pool. (B) HOXA9-mediated expansion of clonogenic myeloid progenitors is blunted in miR-155-deﬁcient BM cells.
5-FU treated wild-type or miR-155
 / (C) BM cells were infected with HOXA9-GFP or GFP control retroviral vectors and then plated for myeloid
colony forming capacity as described in ‘Materials and methods’ section (n=4). There was a signiﬁcant diﬀerence (P<0.018) between HOXA9
induction of myeloid colonies in wild-type BM cells versus miR-155
 / cells. (C) qPCR analysis showing that retroviral-mediated expression of
miR-155 in Hoxa9
 / BM cells produced an  8-fold increase in miR-155 RNA. (D and E) Retroviral-mediated miR-155 expression in either
wild-type or Hoxa9-deﬁcient cells, respectively, resulted in an  2-fold decrease in Pu.1 protein, by western analysis.
5476 Nucleic Acids Research, 2010,Vol.38, No. 16prediction by showing that forced expression of miR-155
does down-regulate Pu.1 protein. While this work was in
progress, others also reported that Pu.1 is a direct target of
miR-155 (38). Taken together, these data provided a
strong working model for HOXA9 mechanism of action
in hematopoiesis and leukemogenesis. We were therefore
surprised that we were unable to demonstrate a regulatory
role for HOXA9 on the Pu.1 protein. We posit that
HOXA9 modulation of miR-155 regulates hematopoiesis
by additional mechanistic pathways that remain to be
described.
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